These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 27681076)

  • 1. Novel biomarkers that assist in accurate discrimination of squamous cell carcinoma from adenocarcinoma of the lung.
    Takamochi K; Ohmiya H; Itoh M; Mogushi K; Saito T; Hara K; Mitani K; Kogo Y; Yamanaka Y; Kawai J; Hayashizaki Y; Oh S; Suzuki K; Kawaji H
    BMC Cancer; 2016 Sep; 16(1):760. PubMed ID: 27681076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Best immunohistochemical panel in distinguishing adenocarcinoma from squamous cell carcinoma of lung: tissue microarray assay in resected lung cancer specimens.
    Kim MJ; Shin HC; Shin KC; Ro JY
    Ann Diagn Pathol; 2013 Feb; 17(1):85-90. PubMed ID: 23040737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung.
    Tsuta K; Tanabe Y; Yoshida A; Takahashi F; Maeshima AM; Asamura H; Tsuda H
    J Thorac Oncol; 2011 Jul; 6(7):1190-9. PubMed ID: 21623236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive immunohistochemistry algorithm for the histological subtyping of small biopsies obtained from non-small cell lung cancers.
    Koh J; Go H; Kim MY; Jeon YK; Chung JH; Chung DH
    Histopathology; 2014 Dec; 65(6):868-78. PubMed ID: 25130792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of clinical characteristics and differential diagnosis of the lung biopsy specimens in 99 adenocarcinoma cases and 111 squamous cell carcinoma cases: utility of an immunohistochemical panel containing CK5/6, CK34βE12, p63, CK7 and TTF-1.
    Xu XY; Yang GY; Yang JH; Li J
    Pathol Res Pract; 2014 Oct; 210(10):680-5. PubMed ID: 25063315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of classifying poorly differentiated non-small cell lung carcinoma biopsies with commonly used lung carcinoma markers.
    Zachara-Szczakowski S; Verdun T; Churg A
    Hum Pathol; 2015 May; 46(5):776-82. PubMed ID: 25776027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6.
    Mukhopadhyay S; Katzenstein AL
    Am J Surg Pathol; 2011 Jan; 35(1):15-25. PubMed ID: 21164283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Diagnostic and Prognostic Roles of Combined Expression of Novel Biomarkers in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma: An Immunohistochemical Study.
    Alabiad MA; Harb OA; Abozaid M; Embaby A; Mandour D; Hemeda R; Shalaby AM
    Iran J Pathol; 2021; 16(2):162-173. PubMed ID: 33936227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue-preserving antibody cocktails to differentiate primary squamous cell carcinoma, adenocarcinoma, and small cell carcinoma of lung.
    Brown AF; Sirohi D; Fukuoka J; Cagle PT; Policarpio-Nicolas M; Tacha D; Jagirdar J
    Arch Pathol Lab Med; 2013 Sep; 137(9):1274-81. PubMed ID: 23289761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples.
    Terry J; Leung S; Laskin J; Leslie KO; Gown AM; Ionescu DN
    Am J Surg Pathol; 2010 Dec; 34(12):1805-11. PubMed ID: 21107086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of the diagnostic difference between the clinical diagnostic criteria and results of immunohistochemical staining of multiple primary lung cancers.
    Nonami Y; Ohtuki Y; Sasaguri S
    J Cardiovasc Surg (Torino); 2003 Oct; 44(5):661-5. PubMed ID: 14735056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of IGF1R expression in non-small-cell lung cancer.
    Nakagawa M; Uramoto H; Oka S; Chikaishi Y; Iwanami T; Shimokawa H; So T; Hanagiri T; Tanaka F
    Clin Lung Cancer; 2012 Mar; 13(2):136-42. PubMed ID: 22133293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glypican-1 is a novel immunohistochemical marker to differentiate poorly differentiated squamous cell carcinoma from solid predominant adenocarcinoma of the lung.
    Kai Y; Amatya VJ; Kushitani K; Kambara T; Suzuki R; Fujii Y; Tsutani Y; Miyata Y; Okada M; Takeshima Y
    Transl Lung Cancer Res; 2021 Feb; 10(2):766-775. PubMed ID: 33718020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal combination of immunohistochemical markers for subclassification of non-small cell lung carcinomas: A tissue microarray study of poorly differentiated areas.
    Noh S; Shim H
    Lung Cancer; 2012 Apr; 76(1):51-5. PubMed ID: 21978426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Desmoglein-3 and Napsin A double stain, a useful immunohistochemical marker for differentiation of lung squamous cell carcinoma and adenocarcinoma from other subtypes.
    Agackiran Y; Ozcan A; Akyurek N; Memis L; Findik G; Kaya S
    Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):350-5. PubMed ID: 22495379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.
    Zhao W; Choi YL; Song JY; Zhu Y; Xu Q; Zhang F; Jiang L; Cheng J; Zheng G; Mao M
    Lung Cancer; 2016 Apr; 94():22-7. PubMed ID: 26973202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma.
    Hamamoto J; Soejima K; Yoda S; Naoki K; Nakayama S; Satomi R; Terai H; Ikemura S; Sato T; Yasuda H; Hayashi Y; Sakamoto M; Takebayashi T; Betsuyaku T
    Mol Med Rep; 2013 Aug; 8(2):456-62. PubMed ID: 23759980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prediction model for distinguishing lung squamous cell carcinoma from adenocarcinoma.
    Li H; Jiang Z; Leng Q; Bai F; Wang J; Ding X; Li Y; Zhang X; Fang H; Yfantis HG; Xing L; Jiang F
    Oncotarget; 2017 Aug; 8(31):50704-50714. PubMed ID: 28881596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility and pattern of positivity of p40 in the diagnosis of squamous cell carcinoma of the lung by cytology: the first study on fine needle aspiration smears.
    Jain D; Mathur SR; Guleria R; Iyer VK
    Cytopathology; 2014 Oct; 25(5):330-5. PubMed ID: 24128123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined high-grade neuroendocrine carcinoma of the lung: clinicopathological and immunohistochemical study of 34 surgically resected cases.
    Yamada K; Maeshima AM; Tsuta K; Tsuda H
    Pathol Int; 2014 Jan; 64(1):28-33. PubMed ID: 24471967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.